SYNYI AI
Provider of Comprehensive Solutions for Medical Big Data
NewMed
Artificial Heart Valve System Developer
RobotGym
Rehabilitation Robotics Developer
Recently, enterprises in Zhangjiang Pharma Valley have accelerated their financing and listing processes to drive the innovative R&D and commercial application of their products.
SYNYI AI Races for Hong Kong IPO
Recently, the Hong Kong Stock Exchange disclosed thatSYNYI AISubmitted a listing application to the Main Board of the Hong Kong Stock Exchange, with China Securities International, CCB International, and BOCOM International as joint sponsors.
SYNYI AI, formerly known as Shanghai Synyi Intelligent Technology Co., Ltd., was established in 2016. Headquartered in Zhangjiang, Shanghai, it is a leading intelligent healthcare technology company in China. The company focuses on the deep integration of artificial intelligence and big data technologies into healthcare scenarios, primarily serving hospitals and healthcare groups.
Since its establishment, SYNYI AI has completed nine rounds of financing, with a cumulative amount exceeding RMB 1.3 billion. Following the final pre-IPO financing round in July 2024, the company’s valuation reached RMB 2.66 billion.
The proceeds from SYNYI AI’s proposed initial public offering (IPO) in Hong Kong are currently intended to be used for the following purposes: strengthening the Company’s research and development capabilities and innovation; enhancing and upgrading its existing products and solutions; improving its commercialization capabilities and establishing a global channel network; acquiring companies that may generate synergies with its existing capabilities; and working capital and other general corporate purposes.
NewMed: Sprinting Toward IPO on the STAR Market
Recently, the official website of the Shanghai Stock Exchange showed thatNewMedIPO on the STAR Market Accepted.
NewMed, established in March 2015, is a high-tech enterprise dedicated to the research and development, production, and sales of transcatheter artificial heart valves and transcatheter ventricular assist systems. For its initial public offering (IPO) on the STAR Market, NewMed has adopted the fifth set of listing criteria, aiming to raise a total of RMB 1.364 billion. The proceeds will be primarily allocated to the construction of production bases for valve systems and catheter-based products and accessories, the establishment of an R&D center, the expansion of its marketing network, as well as supplementing working capital and repaying bank loans.
As of now, NewMed has received approval for the market launch of 11 products, including two valve products and nine accessory products. Among these, Prizvalve® and its second-generation product, Prizvalve Pro®, are the flagship products. In August 2024, Prizvalve® was approved by the National Medical Products Administration (NMPA) for use in patients with symptomatic, calcified, severe degenerative native aortic valve stenosis who are deemed unsuitable for conventional surgical valve replacement following assessment by a heart team using a scoring system. It became the first domestically produced balloon-expandable transcatheter aortic valve replacement (TAVR) system. In June 2025, Prizvalve Pro®, as the second-generation TAVR product, also received NMPA approval for market launch.
RobotGym Completes Pre-A Funding Round Worth Hundreds of Millions of Yuan
Recently,RobotGymAnnounces Completion of RMB 100 Million Pre-A Financing Round, Co-Invested by Renowned Healthcare Fund Qingsong Capital, Leading Computing Power Listed Company Runze Technology, and Pinghu Zexin. The Proceeds Will Be Used to Accelerate the Deployment of Embodied AI in Elderly Care Institutions and Home Settings.
RobotGym was established in June 2023, focusing on the research and development of embodied intelligent robots for rehabilitation and elderly care scenarios. It is dedicated to addressing the caregiving challenges faced by individuals with disabilities, partial disabilities, and the advanced elderly. Starting from real-world elderly care scenarios, the company acquires task data through the continuous operation of robots in authentic environments, driving iterative improvements in model capabilities through data. This approach gradually forms a closed-loop evolutionary system of “scenario–data–model–scenario.” Within this system, real-world scenarios are used to continuously generate and validate capabilities, operational data serves as core training assets, and models continuously evolve through real-world tasks, thereby enhancing scenario-specific capabilities.
Along this technological roadmap, the company has launched the world’s first dual-modal embodied elderly care robot capable of both passenger transport and service tasks, achieving the integration of mobile transportation and proactive caregiving capabilities.
MindRank Completes $52 Million Series B Financing
Recently,MindRankAnnounced the phased completion of a cumulative $52 million Series B financing round, with joint investment from multiple renowned institutional investors and industrial funds. Kaicheng Capital served as the exclusive financial advisor for this round.
Founded in 2021, Derwise Pharma established its R&D center in Zhangjiang. The founder and CEO, Niu Zhangming, brings years of experience as CTO of a publicly listed AI healthcare company in Germany. The company has secured three Investigational New Drug (IND) approvals to date and maintains a pipeline of 5–7 preclinical candidate compounds (PCCs).
The proceeds from this round of financing will be primarily invested in the deep technical iteration of the company’s proprietary, end-to-end AI drug discovery engine, MAP (Molecule Arts Platform), to continuously enhance its industry-leading Multi-Agent collaborative system and Clinical Data-in-the-Loop framework, while advancing core pipeline candidates from clinical development to commercialization and accelerating the expansion of a differentiated portfolio of innovative drugs.
Compiled from: Win-Win Pudong, STAR Market Daily, Arterial Network, and Corporate Official WeChat Accounts